Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Enalaprilat Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE known ✓ | P12821 | 13/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Enalaprilat Anhydrous SCHEMBL12737170 | 1.00 | ACE (1.00) | ACELMNASMN1; SMN2 | |
| Enalaprilat Anhydrous SCHEMBL18033873 | 1.00 | ACE (1.00) | ACELMNASMN1; SMN2 | |
| Enalaprilat Anhydrous SCHEMBL2406720 | 1.00 | ACE (1.00) | ACELMNASMN1; SMN2 | |
| Enalaprilat Anhydrous SCHEMBL37289 | 1.00 | ACE (1.00) | ACELMNASMN1; SMN2 | |
| Enalaprilat Anhydrous SCHEMBL11204535 | 1.00 | ACE (1.00) | ACELMNASMN1; SMN2 | |
| Enalaprilat Anhydrous SCHEMBL24327564 | 1.00 | ACE (1.00) | ACELMNASMN1; SMN2 | |
| Enalaprilat Anhydrous SCHEMBL6106603 | 1.00 | ACE (1.00) | ACELMNASMN1; SMN2 | |
| Enalaprilat Anhydrous SCHEMBL8149345 | 0.99 | ACE (0.98) | ACELMNASMN1; SMN2 | |
| Enalaprilat Anhydrous SCHEMBL21046169 | 0.99 | ACE (0.98) | ACELMNASMN1; SMN2 | |
| Enalaprilat Anhydrous SCHEMBL37288 | 0.99 | ACE (0.98) | ACELMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060104913-A1 | Inhalable formulations for treating pulmonary hypertension and methods of using same | MERCK PATENT GMBH | 2006-05-18 | — | — | US | claimed |
| US-20040265238-A1 | Inhalable formulations for treating pulmonary hypertension and methods of using same | DEY PHARMA, L.P. (F/K/A DEY L.P.) | 2004-12-30 | — | — | US | claimed |
| US-20030105327-A1 | Process for preparing pharmacologically acceptable salt of N-(1(S)-ethoxycarbonyl-3-phenylpropyl)-L-alanyl-amino acid | KANEKA CORPORATION (JP) | 2003-06-05 | — | — | US | claimed |
| US-6518436-B2 | Condensing an amino acid and N-(1(S)-ethoxycarbonyl-3-phenylpropyl)-L-alanine-N-carboxy-anhydride; suppressing the by-product diketopiperazine derivative; making enalapril maleate | KANEKA CORPORATION (JP) | 2003-02-11 | — | — | US | claimed |
| US-20020087007-A1 | Process for preparing pharmacologically acceptable salt of N-(1(S)-ethoxycarbonyl-3-phenylpropyl)-L-alanyl-amino acid | KANEKA CORPORATION (JP) | 2002-07-04 | — | — | US | claimed |
| US-6204393-B1 | IN AQUEOUS SOLUTION; CONTROLLING PH; NEUTRALIZATION | KANEKA CORPORATION (JP) | 2001-03-20 | — | — | US | claimed |
| EP-1018516-A1 | METHOD FOR CRYSTALLIZING MALEIC ACID SALT OF N-(1(S)-ETHOXYCARBONYL-3-PHENYLPROPYL)-L-ALANYL-L-PROLINE | KANEKA CORPORATION (JP) | 2000-07-12 | — | — | EP | claimed |
| EP-0967221-A1 | PROCESS FOR PREPARING PHARMACOLOGICALLY ACCEPTABLE SALTS OF N-(1(S)-ETHOXYCARBONYL-3-PHENYLPROPYL)-L-ALANYL AMINO ACIDS | KANEKA CORPORATION (JP) | 1999-12-29 | — | — | EP | claimed |
| US-5238924-A | Treatment of renal diseases with ace inhibitors | MERCK & CO., INC. (US) | 1993-08-24 | — | — | US | claimed |
| EP-0463636-A2 | Cardiovascular composition | MERCK FROSST CANADA INC. (CA) | 1992-01-02 | — | — | EP | claimed |
| EP-0129136-B1 | ANTIHYPERTENSIVE COMPOSITION | MERCK & CO. INC. (US) | 1991-10-30 | — | — | EP | claimed |
| US-4663307-A | Anti-allergic and anti-thromboembolic 6H-dibenz-[b,e][1,4]-oxathiepin derivatives, compositions, and method of use therefor | MERCK FROSST CANADA, INC. (CA) | 1987-05-05 | — | — | US | claimed |
| EP-0166257-A2 | Cardiovascular composition | MERCK FROSST CANADA INC. (CA) | 1986-01-02 | — | — | EP | claimed |
| EP-0129136-A2 | Antihypertensive composition | MERCK & CO. INC. (US) | 1984-12-27 | — | — | EP | claimed |
| US-4472384-A | INTERPHENYLENE 9-THIA-11-OXO-12-AZA PROSTANOIC ACID DERIVATIVE AND CARBOXYALKYLDIPEPTIDE | MERCK & CO., INC. (US) | 1984-09-18 | — | — | US | claimed |
| EP-0079521-A1 | Process for preparation of carboxyalkyldipeptide derivatives | MERCK & CO. INC. (US) | 1983-05-25 | — | — | EP | claimed |
| US-4374829-A | Aminoacid derivatives as antihypertensives | MERCK & CO., INC. (US) | 1983-02-22 | — | — | US | claimed |
| EP-0012401-A1 | Carboxyalkyl dipeptide derivatives, process for preparing them and pharmaceutical composition containing them | MERCK & CO. INC. (US) | 1980-06-25 | — | — | EP | claimed |
| JP-2131496-A | — | — | None | — | — | JP | disclosed |
| EP-0012401-A1 | Carboxyalkyl dipeptide derivatives, process for preparing them and pharmaceutical composition containing them | MERCK & CO. INC. (US) | 1980-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105327-A1 | Process for preparing pharmacologically acceptable salt of N-(1(S)-ethoxycarbonyl-3-phenylpropyl)-L-alanyl-amino acid | SLC7A1, ASS1, ALDH7A1 | ACE 67/4885LMNA 765/4885SMN1; SMN2 496/4885 |
| US-20020087007-A1 | Process for preparing pharmacologically acceptable salt of N-(1(S)-ethoxycarbonyl-3-phenylpropyl)-L-alanyl-amino acid | SLC7A1, ASS1, ALDH7A1 | ACE 67/4885LMNA 765/4885SMN1; SMN2 496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.